Technavio, a tech-focused market research firm, has published a new report on the global venous thromboembolism therapeutic market, which is expected to grow at a CAGR of over 6% during the calculated period 2017-2021.
Based on geographical segmentation, Technavio market researchers categorize the global venous thromboembolism therapeutic market into the following important regions: the Americas, APAC, and EMEA.
Click here to request a free sample of this report
VTE Therapeutics market in Americas: The growing demand for factor Xa inhibitors will drive the market growth in the Americas during the forecast period. The introduction of NOACs will help the vendors generate more revenues in the American market. The US will emerge as the key revenue generator in the American market over the period of next four years. The market is also driven by the increased specificity and efficacy of these drugs in the market. The benefits associated with Factor Xa inhibitors and direct thrombin inhibitors will increase its adoption rates in the region.
According to Sapna Jha, a lead analyst at Technavio, specializing in research on cardiovascular and metabolic disorders, “The vendors are focusing on developing reversal agents to boost the sales of NOACs in the American market. The increase in the number of drug approvals by the FDA will help the vendors launch more effective products in the market. For instance, the antidote Praxbind received the FDA’s approval in October 2015.”
VTE Therapeutics market in EMEA: The rising awareness and established healthcare infrastructure in Europe will lead to higher demand for VTE in the EMEA market. Countries like the UK, Spain, Italy, Germany, and France are witnessing a high demand for factor Xa inhibitors. The growing awareness of the benefits associated with these agents will lead to an increase in the adoption rates in the region. The launch of new product launches such as Boehringer Ingelheim’s Pradaxa and Daiichi Sankyo’s Lixiana will help the manufacturers attract more consumers.
VTE Therapeutics market in APAC: The rising number of government initiatives to renovate hospitals will help create quality laboratories and have a positive impact on the growth of venous thromboembolism therapeutic market in the region. The increasing incidents of cancer and hip and knee related surgeries will help APAC to be the fastest growing region in the global market. The introduction of new drugs will help the global vendors expand their businesses in the APAC market during the forecast period.
Ask an analyst to know more about this report
The leading retailers functioning in the global venous thromboembolism therapeutic market are:
- Bayer HealthCare
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Johnson & Johnson
- Sanofi
Other prominent sellers in the market comprise of Altor Bioscience, Armetheon, Aspen Pharma, BioInvent International, eXIthera Pharmaceuticals, Gamma Therapeutics, GlycoMimetics, Green Cross, Isis Pharmaceutical, Leo Pharma, Pfizer, Portola Pharmaceuticals, and ThromboGenics.
A more detailed analysis is available in the Technavio report titled, ‘Global Venous Thromboembolism Therapeutic Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Diabetic Therapeutic Market 2017-2021
- Global Intraosseous Infusion Devices Market 2017-2021
- Anticoagulants Market in the US 2016-2020
To read more press releases – click here
